CSL Limited Company Profile (ASX:CSL)

Analyst Ratings

Consensus Ratings for CSL Limited (ASX:CSL) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for CSL Limited (ASX:CSL)
Show:
DateFirmActionRatingPrice TargetActions
9/4/2014Deutsche Bank AGUpgradeBuy$76.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/21/2014Credit Suisse Group AGReiterated RatingOutperform$74.55View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for CSL Limited (ASX:CSL)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for CSL Limited (ASX:CSL)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for CSL Limited (ASX:CSL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for CSL Limited (ASX:CSL)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for CSL Limited (ASX:CSL)
DateHeadline
07/22/16 02:50 PMPlasma Therapy Market Worth 297.6 Million USD by 2021
07/21/16 08:55 PMDecks cleared for CSL's dry dock
07/21/16 10:48 AMNew Cochin Shipyard Limited Dry Dock Gets OK
07/21/16 10:48 AMIntravenous Immunoglobulin (IVIg) Market : Opportunities and Forecasts,2014 to 2020
07/21/16 10:48 AMNew Zealand shares hit new highs, Australia joins rally
07/20/16 11:17 AMETF’s with exposure to CSL Ltd. : July 20, 2016 -
07/20/16 10:18 AMCSL Plasma Raises Over $118,000 For The Immune Deficiency Foundation - [PR Newswire] - BOCA RATON, Fla., July 20, 2016 /PRNewswire/ -- CSL Plasma Inc., one of the world's largest collectors of human plasma, has set a new giving record for their donation to the Immune Deficiency Foundation (IDF). During the months of April through June, CSL Plasma donors and employees raised over $118,000. "Year after year, CSL Plasma demonstrates their incredible commitment to people with primary immunodeficiency diseases by raising record funds for the Immune Deficiency Foundation," said Marcia Boyle, IDF President and Founder. The funds will support the vital resources that we provide to thousands of individuals and families living primary immunodeficiency.
07/19/16 03:31 PMFDA approves CSL Behring's Berinert for use in children under 12
07/19/16 03:31 PMFDA approves CSL Behring's Berinert for use in children under 12
07/19/16 03:31 PMCSL : U.S. FDA Approves CSL Behring's Berinert as the First and Only Pediatric Treatment for Hereditary Angioedema (HAE)
07/19/16 03:31 PMCSL : U.S. FDA Approves CSL Behring's Berinert as the First and Only Pediatric Treatment for Hereditary Angioedema (HAE)
07/19/16 09:00 AMCSL Behring to Present New Data for IDELVION® and AFSTYLA® at the World Federation of Hemophilia 2016 World Congress - [PR Newswire] - KING OF PRUSSIA, Pa., July 19, 2016 /PRNewswire/ -- CSL Behring announced today that it will present new data from its recombinant coagulation factor development programs at the XXXII International Congress ...
07/18/16 10:55 AMU.S. FDA Approves CSL Behring's Berinert® as the First and Only Pediatric Treatment for Hereditary Angioedema (HAE) - [PR Newswire] - KING OF PRUSSIA, Pa., July 18, 2016 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved the use of Berinert , its therapy ...
07/14/16 08:57 PM4 reasons to buy CSL Limited shares
07/14/16 03:39 PMAnti-Infective Vaccines Market Value Chain and Forecast 2016-2026
07/13/16 10:25 AMComstock Completes Shares for Debt Transactions
07/12/16 11:56 PMCSL Ltd. breached its 50 day moving average in a Bullish Manner : CSL-AU : July 13, 2016 -
07/12/16 07:44 AMFormer Czech star seeks cooperation with CSL on youth training
07/11/16 06:01 PMSeqirus is first-to-market with shipment of seasonal influenza vaccines to the US for the 2016-2017 season - [PR Newswire] - HOLLY SPRINGS, N.C., July 11, 2016 /PRNewswire/ -- Seqirus announced today that it has begun shipment of its portfolio of influenza vaccines to customers in the US market for the 2016-2017 season. The ...
07/07/16 09:43 AMIntravenous Immunoglobulin (IVIg) Market : Share, Size, Competitive Strategies and Forecast 2014 – 2020
07/06/16 03:31 PMCSL Reach New Levels with Integrated Processing and Packaging Solutions
07/06/16 03:31 PMCSL Completes Management Buyout and Adds Strategic Investor
07/06/16 03:31 PMThe bargain hunter’s guide to CSL Limited
07/05/16 03:23 PMGlobal Blood Plasma Market Report 2016 - Growing Demand for Immunoglobulin to Drive Blood Plasma Market - Research and Markets
07/05/16 08:08 AM10 Brokers Traded N98.430 Billion Shares in June
07/05/16 08:08 AMIn-depth report on hemophilia a - pipeline review, H2 2015 just published
07/03/16 08:31 PMCSL to Support new Biopharmaceutical Training Centre at UQ - [at noodls] - Melbourne, Australia - 04/07/2016 CSL is pleased to announce it will be an inaugural partner of the new Australian Research Council Industrial Transformation Training Centre for Biopharmaceutical Innovation ...
07/01/16 03:26 PMRed Biotechnology Market Technological Breakthroughs and Current Trends
06/30/16 11:23 PMCSL Ltd. breached its 50 day moving average in a Bullish Manner : CSL-AU : July 1, 2016 -
06/30/16 08:02 PMVaccine Adjuvants Market by Product Type , Route of Administration , Disease Type , Application & Application Category - Forecasts to 2021
06/30/16 08:02 PMWhy CSL Limited is one of the best stocks on the ASX
06/29/16 08:29 PMBonhams Auction Sees 1972 BMW 3.0 CSL Sold for $137,000
06/29/16 03:24 PMReport explores the global intravenous immunoglobulin market 2016: industry size, shares growth, analysis and forecast to 2020
06/28/16 03:24 PMCan Concomitant Flu, PCV, and DTaP Vaccines Affect Febrile Seizure Risk?
06/28/16 03:24 PMGlobal vaccine market is estimated to exceed USD 59.20 billion in 2020
06/28/16 03:24 PMCSL Limited shares could be a great buy today
06/25/16 07:18 AMDry dock: CSL clears the air on eco concerns
06/23/16 04:30 AMCSL Behring Announces Immunoglobulin Research Grant Winners - [PR Newswire] - KING OF PRUSSIA, Pa., June 23, 2016 /PRNewswire/ -- CSL Behring announced today at the Peripheral Nerve Society's Inflammatory Neuropathy Consortium (INC) meeting at the University of Glasgow, Scotland, ...
06/22/16 08:40 PMCSL : Behring hemophilia treatment approved and available
06/22/16 03:35 PMPlasma Fractionation 2016 Global Market Share,Supply,Company Profiles and Market Opportunities Research Report Forecasting to 2022
06/22/16 03:35 PMCSL : AFSTYLA - CSL Behring's Novel Recombinant Factor VIII Single Chain Therapy for Hemophilia A - Now Available in the U.S.
06/21/16 08:08 AMCSL Behring hemophilia treatment approved and available
06/20/16 03:22 PMBlood Plasma Derivatives 2016 World Market Share,Supply,Company Profiles and Market Opportunities Research Report Forecasting to 2022
06/20/16 08:00 AMAFSTYLA® - CSL Behring's Novel Recombinant Factor VIII Single Chain Therapy for Hemophilia A - Now Available in the U.S. - [PR Newswire] - KING OF PRUSSIA, Pa., June 20, 2016 /PRNewswire/ -- Driven by its promise to save lives, CSL Behring announced today that AFSTYLA ® , its novel long-lasting ...
06/18/16 03:10 PMCSL delivers vessel before schedule
06/17/16 10:13 AMVaccine Adjuvants Market To Soar At A CAGR Of 10.5% To Hit $769.4 Million By 2021
06/17/16 10:13 AMCSL delivers patrol vessel to Coast Guard
06/17/16 10:13 AMThe bargain hunter’s guide to Sirtex Medical Limited
06/15/16 03:32 PMGlobal Market for Vaccine to Reach 59.2 Billion by 2020, Growing at CAGR of 11.0% by 2020
06/15/16 03:32 PMVaccine Adjuvants Market Worth 769.4 Million USD by 2021

Social

About CSL Limited

CSL Limited logoCSL Limited is a biopharmaceutical company that researches, develops, manufactures and markets biotherapies to treat and prevent serious and rare medical conditions. The principal activities of the Company include research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. The Company operates through the three segments: CSL Behring, which manufactures and develops plasma therapies (plasma products and recombinants), bioCSL, which manufactures and distributes non-plasma biotherapeutic products, and CSL Intellectual Property, which includes licensing of intellectual property generated by the Company to unrelated third parties. CSL Behring therapies are indicated for treatment of bleeding disorders including, hemophilia and von Willebrand disease, primary and secondary immune deficiencies, hereditary angioedema, neurological disorders and inherited respiratory disease. bioCSL manufactures seasonal and pandemic influenza vaccines.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: ASX
  • Symbol: CSL
  • CUSIP:
Key Metrics:
  • Previous Close: $90.16
  • 50 Day Moving Average: $112.50
  • 200 Day Moving Average: $107.06
  • P/E Ratio: 39.62
  • P/E Growth: 3.45
  • Market Cap: $55.08B
  • Current Year EPS Consensus Estimate: $ EPS
  • Next Year EPS Consensus Estimate: $ EPS
Additional Links: